Newest Second-Generation Antipsychotics and Their Indications
The newest second-generation antipsychotics include lumateperone (ITI-007), olanzapine-samidorphan combination, and SEP-363856, with emerging long-acting injectable formulations including aripiprazole lauroxil NanoCrystal® and Perseris (RBP-7000) for subcutaneous administration.
Recently Approved Agents
Olanzapine-Samidorphan Combination
This combination specifically targets reduced weight gain liability while maintaining olanzapine's efficacy for schizophrenia treatment 1. The samidorphan component is designed to mitigate one of olanzapine's most problematic adverse effects—metabolic dysregulation—without compromising therapeutic benefit. The 2025 INTEGRATE guidelines recommend this combination as a second-line option, specifically noting "olanzapine (with either samidorphan combination or concurrent metformin)" 2.
Lumateperone (ITI-007)
This agent targets total symptoms in schizophrenia and represents a novel pharmacological approach 1. It is among the emerging therapies being investigated for broader symptom coverage beyond traditional positive symptom control.
SEP-363856
A trace amine-associated receptor-1 (TAAR1) agonist that targets total symptoms, representing an entirely novel mechanism distinct from traditional dopamine D2 antagonism 1. This is particularly significant as it may avoid typical dopaminergic side effects.
Novel Long-Acting Injectable Formulations
Aripiprazole Lauroxil NanoCrystal®
FDA-approved formulation that achieves therapeutic levels within 24 hours without need for initial oral co-treatment or loading injection strategies 1. This represents a significant advancement over earlier LAI formulations that required oral supplementation during initiation.
Perseris (RBP-7000)
The first subcutaneous injectable LAI antipsychotic (risperidone-based), also achieving therapeutic levels within 24 hours 1. The subcutaneous route offers advantages in administration ease and patient acceptance compared to intramuscular injections.
Extended-Interval Formulations
- Paliperidone palmitate 6-monthly intramuscular formulation (under investigation) 1
- Aripiprazole lauroxil 6-week and 8-week administration preparations 3
- Paliperidone palmitate 3-monthly injection—the first LAI to extend beyond monthly dosing 3
Agents Under Investigation
For Negative Symptoms
- Roluperidone (MIN-101): Sigma-2/5-HT2A antagonist 1
- Pimavanserin: 5-HT2A inverse agonist 1
- TAK-831: D-amino acid oxidase (DAAO) inhibitor 1
For Cognitive Dysfunction
- BI-425809: Glycine transporter-1 inhibitor 1
- Cannabidiol: Targets both cognitive symptoms and total symptoms 1
For Treatment-Resistant Schizophrenia
- Sodium benzoate: DAAO inhibitor for residual positive symptoms 1
- LuAF-35700: Dopamine D1/D2 antagonist 1
Clinical Context from Current Guidelines
The 2025 INTEGRATE guidelines emphasize that first-generation and second-generation antipsychotics are not distinct categories from either a pharmacological or clinical perspective, and this classification should not guide psychotropic choice 2. Instead, selection should be based on:
- Side-effect profiles through shared decision-making
- Pharmacodynamic profiles when switching (attempting different receptor mechanisms)
- Specific formulation advantages (e.g., LAI availability, dosing convenience)
For second-line treatment after D2 partial agonist failure, the guidelines specifically recommend amisulpride, risperidone, paliperidone, or olanzapine (with either samidorphan combination or concurrent metformin) 2.
Important Caveats
Most of these trial programs are still ongoing or have yielded mixed or even negative results 1. The agents targeting negative symptoms and cognitive dysfunction represent areas of greatest unmet need, but evidence remains preliminary. The olanzapine-samidorphan combination and new LAI formulations have the strongest approval status and evidence base among the "newest" agents.
Barriers to LAI use persist despite their advantages, including lack of patient trust (57.5%), hospital supply issues (43.8%), and limited clinician experience (36.3%) 4. Education of both patients and clinicians remains critical for implementation.